Cargando…

Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device

BACKGROUND: Administering growth-hormone therapy (GHT) is a long-term treatment, associated with avoidance and phobic behaviors in the children involved. The current study examined GHT users’ perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared...

Descripción completa

Detalles Bibliográficos
Autor principal: Kaptein, Ad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728268/
https://www.ncbi.nlm.nih.gov/pubmed/23926423
http://dx.doi.org/10.2147/PPA.S46990
_version_ 1782278832539041792
author Kaptein, Ad A
author_facet Kaptein, Ad A
author_sort Kaptein, Ad A
collection PubMed
description BACKGROUND: Administering growth-hormone therapy (GHT) is a long-term treatment, associated with avoidance and phobic behaviors in the children involved. The current study examined GHT users’ perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared to the traditional device. METHODS: A total of 73 persons participated (mean age ± standard deviation, 10.10 ± 3.60 years) in a longitudinal design. Users’ views were studied 4 weeks after having applied both the old and the new device for a period of at least 4 weeks. Satisfaction, ease and frequency of restitution, local sensations, bruises during administering GHT, affective response to local sensations, and subject preference were assessed on the basis of the users’ responses. RESULTS: Subjects’ satisfaction with the new device was equal compared with the previous device for the total group of 73 children. However, the subgroup of 59 children who proved tolerant to meta-cresol (new preservative for Vision X only) reported a significantly higher satisfaction rating with the new device compared to the old device (7.7 vs 6.6, P=0.0002). Vision X was evaluated as better on ease and frequency of restitution and the number of bruises. Pain sensations did not differ meaningfully between the two devices. The new device was favored over the previous one in a majority of respondents. Vision X allows easy reconstitution of the solution, which was reflected in the percentage of young children able to prepare transjections themselves being more than doubled, illustrating the greater sense of empowerment in these users. Self-reported adherence to the therapy was good (less than 10% of injections missed) with both devices. CONCLUSION: The new device ZomaJet Vision X appears to be evaluated more positively than the previous version on criteria that refect users’ preferences.
format Online
Article
Text
id pubmed-3728268
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37282682013-08-07 Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device Kaptein, Ad A Patient Prefer Adherence Original Research BACKGROUND: Administering growth-hormone therapy (GHT) is a long-term treatment, associated with avoidance and phobic behaviors in the children involved. The current study examined GHT users’ perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared to the traditional device. METHODS: A total of 73 persons participated (mean age ± standard deviation, 10.10 ± 3.60 years) in a longitudinal design. Users’ views were studied 4 weeks after having applied both the old and the new device for a period of at least 4 weeks. Satisfaction, ease and frequency of restitution, local sensations, bruises during administering GHT, affective response to local sensations, and subject preference were assessed on the basis of the users’ responses. RESULTS: Subjects’ satisfaction with the new device was equal compared with the previous device for the total group of 73 children. However, the subgroup of 59 children who proved tolerant to meta-cresol (new preservative for Vision X only) reported a significantly higher satisfaction rating with the new device compared to the old device (7.7 vs 6.6, P=0.0002). Vision X was evaluated as better on ease and frequency of restitution and the number of bruises. Pain sensations did not differ meaningfully between the two devices. The new device was favored over the previous one in a majority of respondents. Vision X allows easy reconstitution of the solution, which was reflected in the percentage of young children able to prepare transjections themselves being more than doubled, illustrating the greater sense of empowerment in these users. Self-reported adherence to the therapy was good (less than 10% of injections missed) with both devices. CONCLUSION: The new device ZomaJet Vision X appears to be evaluated more positively than the previous version on criteria that refect users’ preferences. Dove Medical Press 2013-07-24 /pmc/articles/PMC3728268/ /pubmed/23926423 http://dx.doi.org/10.2147/PPA.S46990 Text en © 2013 Kaptein, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Kaptein, Ad A
Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title_full Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title_fullStr Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title_full_unstemmed Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title_short Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
title_sort transjecting growth hormone: continuous nightmare or controlled nuisance? evaluation of a new needle-free device
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728268/
https://www.ncbi.nlm.nih.gov/pubmed/23926423
http://dx.doi.org/10.2147/PPA.S46990
work_keys_str_mv AT kapteinada transjectinggrowthhormonecontinuousnightmareorcontrollednuisanceevaluationofanewneedlefreedevice